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CHAPTER 1
INTRODUCTION
Global epidemiologic studies indicate that habitual ingestion of high levels of
dietary salt is associated with elevated blood pressure (BP) (Stamler, 1997).
Accordingly, one estimate suggests that approximately 58% of Americans with
hypertension are salt sensitive (e.g., increased sodium intake elevates their arterial
pressure and/or decreased sodium intake lowers their arterial pressure) (Weinberger,
Fineberg, Fineberg, et al., 2001). Salt sensitivity is more frequently observed in African
American than in Caucasian subjects, and in older than in younger subjects (Luft, Miller,
Grim, et al., 1991).

Salt sensitivity is so prevalent in African Americans that it is

considered to be a “hallmark” of Black hypertension, as 73% of African American
hypertensive patients are found to be salt sensitive (Svetkey, Chen, McKeown, et al.,
1997). Salt sensitivity has also been linked to obesity (Flack, Grimm, Staffileno, et al.,
2002; Rocchini, Key, Bondie, et al., 1989), increased activation of the renin-angiotensin
system (RAS), and relative deficiency of nitric oxide (NO) (Hall, Brands, Henegar, 1999;
Adelman, 2002), in both African Americans and Caucasians.
The mechanism or mechanisms resulting in salt-sensitive hypertension are
multiple and include both activation of the RAS via increases in angiotensin II and
reductions in the endogenous vasodilator, NO (Figure 1). Oxidative stress reflected by
release of reactive oxygen species (ROS) such as, superoxide anion (O2–) has several
deleterious physiological effects, most importantly a reduction of NO bioactivity.
Increased dietary sodium downregulates NO, upregulates vascular angiotensin II, and
raises oxidative stress via upregulation of NADPH oxidase (Zhou, Adam, Jaimes, 2003;
Boddi, Poggesi, Coppo, et al., 1998). An important means of NO downregulation is
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Figure 1. Proposed Model of the Sodium-Induced Reduction in Nitric Oxide and
Elevation in Arterial Pressure in African Americans. Factors (i.e. obesity, high dietary
sodium) associated with salt sensitivity increase vascular angiotensin II and
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and reduce superoxide
dismutase (SOD), an important scavenger of reactive oxygen species. The elevations
of vascular angiotensin II and NADPH oxidase and reduction of SOD increase the
presence of reactive oxygen species (ROS), which depress the expression and activity
of dimethylarginine dimethylaminohydrolase (DDAH). The DDAH enzyme catalyzes the
degradation of asymmetric dimethylarginine (ADMA), an inhibitor of nitric oxide (NO)
synthase. Thus, DDAH depression by ROS results in the accumulation of ADMA, which
decreases NO production. In the setting of ad lib sodium intake, the reduction in NO
results in impaired natriuresis that causes a rise in systemic pressure to augment renal
pressure-natriuresis, thereby maintaining steady state volume homeostasis. In the
setting of ad lib potassium intake, potassium stimulates kallekrein release converting
kininogen to bradykinin which increases NO release. 1Blood pressure (BP) rises to
stimulate natriuresis thereby restoring tissue perfusion homeostasis due to the NO
deficiency that has shifted the pressure-natriuresis curve rightward (to higher BP).
Thus, in a sodium-replete environment, tissue perfusion homeostasis is maintained at
the expense of higher BP. It is plausible but not known if the sodium-induced rise in
ADMA is attributable to a parallel depression in DDAH by sodium.
through asymmetric dimethylarginine (ADMA), an endogenous NO inhibitor, which is
largely metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH).
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The activity of DDAH is impaired by oxidative stress, thereby permitting ADMA to
accumulate thus resulting in further inhibition of NO [↑ROS  ↓DDAH  ↑ADMA 
↓NO]. Increases in oxidative stress, reduction in DDAH activity, and augmented action
of ADMA on depressing NO production represents a plausible mechanism in human salt
sensitivity. To date, we are unaware of studies that have examined the sodium-induced
effect of DDAH activity resulting in this cascade.
Therefore, the purpose of this study is to investigate and characterize the above
mechanism through which salt-induced depression of NO synthesis occurs in
normotensive African Americans. The central hypothesis is that increased dietary
sodium intake downregulates DDAH leading to increased ADMA which depresses
NO production, resulting in a rise in BP. I further postulate that ROS will increase
with sodium exposure, resulting in downregulation of DDAH. This initial study is
the first to test whether increased sodium intake is associated with a reduction in DDAH
activity, leading to an increase in ADMA, and a decrease in NO production as
determined by fewer NO metabolites.

The study was conducted in healthy,

normotensive African American men and women.
Hypertension in African Americans is a major clinical and public health problem
that contributes significantly to premature morbidity and mortality as well as to the
shorter lifespan in African Americans compared to Caucausians.

Higher BP

measurements in African Americans compared to Caucasians have been documented
early in life, beginning in childhood (Muntner, He, Chen, et al., 2004). The age-adjusted
prevalence of hypertension (HTN) during 2006 among individuals aged 20 years and
older in the total US population was 33.3% (73,600,000). Non-Hispanic Blacks had the
highest age-adjusted prevalence (44.4% men, 43.9% women), non-Hispanic Whites an
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intermediate prevalence (34.1% men, 30.3% women), and Mexican Americans the
lowest prevalence (23.1% men, 30.4% women) (Lloyd-Jones, Adams, Carnethon, et al.,
2009).
Diet and lifestyle likely play important roles in the pathogenesis of HTN in African
Americans and in the greater incidence of HTN relative to Caucasians.

African

Americans, especially women, are less physically active, consume more calories and
are more obese beginning in the pre-adult years than Caucasians (Burke, Savage,
Manolio, et al., 1992; Sharp, Bell, Grunwald, et al., 2002). Obesity, especially among
women, is more common in African Americans than Caucasians (Ogden, Carroll, Curtin,
et al., 2006).
Salt sensitivity is associated with a rise in BP occurring during sodium loading
and/or a fall in BP during sodium restriction that exceeds directionally appropriate
random fluctuations in BP. Salt sensitivity is more common in African American than
Caucasian hypertensives and is also present, albeit to a lesser degree, in normotensive
African Americans (Wright, Rahman, Scarpa, et al., 2003). Nevertheless, more than
50% of both African Americans and Caucasians with hypertension will manifest salt
sensitivity (Peters and Flack, 2000). Salt sensitivity is a very practical concern given the
nearly ubiquitous intake of dietary sodium by Americans in general and African
Americans in particular, that is far in excess of any known physiological need. Even
those African Americans with BPs in the normal range, have typically been found to
manifest more salt sensitivity than Caucasians (Flack, Ensrud, Mascioli, et al., 1991).
The acute phase of salt sensitivity is associated with transient plasma volume
expansion and increased cardiac output leading to increased tissue perfusion. The
chronic phase of salt sensitivity is, however, characterized by a return of cardiac output
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to normal and only those manifesting an increase in peripheral vascular resistance
actually manifest a presssor response to sodium. Arguably, salt sensitivity has been
conceptualized as maintenance of tissue perfusion homeostasis at the expense of
higher blood pressure levels that augment pressure-induced renal natriuresis.

Salt

sensitivity increases at higher levels of BP, while plasma volume is simultaneously
lower (frankly depressed) at higher BP levels. Thus, it is unlikely that salt sensitivity is a
physiological attempt to maintain intravascular homeostasis but rather is a physiologic
means for normalizing tissue perfusion via an incompletely understood mechanism(s) of
whole-body autoregulation. The level of BP required to maintain steady state in/out
tissue perfusion homeostasis can be influenced by factors such as nitric oxide
deficiency and/or higher levels of angiotensin II, two factors that shift the pressurenatriuresis curve to the right. The pressure natriuresis relationship becomes less steep
in those with salt sensitivity as higher arterial pressures are required to excrete any
given amount of sodium compared to those who do not manifest salt sensitivity; it is the
excretion of urinary sodium along with the rise in peripheral resistance that restores and
maintains tissue perfusion homeostasis. In individuals or groups prone to salt sensitivity
(those with impairments in natriuresis), the consumption of a typical western diet that
contains sodium far in excess of physiological requirements, will likely lead to sustained
BP elevations.
Although the physiological and genetic factors underlying salt sensitivity are
increasingly understood, the mechanisms involved are not fully elucidated.

This

experimental study will assess the effect of sodium loading on an important physiologic
cascade that has been hypothesized to contribute to salt-sensitive hypertension. This is
an initial study used as basic exploratory work to establish a conceptual and plausible
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model for future research. The study will enhance our knowledge in the field of saltsensitive hypertension by potentially delineating a mechanism which can be targeted
with lifestyle modifications (e.g., raised potassium intake) and via pharmacological
means (e.g., DDAH stimulators) to prevent the rise in BP during habitually high dietary
sodium intake.
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CHAPTER 2
BACKGROUND AND SIGNIFICANCE
There are a number of obesity-related physiological effects that contribute to the
intermediate BP phenotype, salt sensitivity (Rocchini, 2000; Hall, Henegar, Dwyer, et
al., 2004) as well as resistance to hypertensive drug therapy (Taler, 2005; Cushman,
Ford, Cutler, et al., 2002) which is, in turn, at least partially mediated by salt sensitivity.
Physical activity improves endothelial function, primarily via the augmented release of
nitric oxide (NO) and reduced NO destruction attributable to lower levels of oxidative
stress (Franzoni, ghiadoni, Galetta, et al., 2005; Rush, Denniss, Graham, 2005) and
greater NO release from the vascular endothelium. Long-term dietary patterns plausibly
impact long-term trends in BP. Increased dietary sodium intake raises BP, at least in
susceptible people.

There is also evidence that increased dietary sodium intake

augments vascular angiotensin generation (Boddi, Poggesi, Coppo et al., 1998) while,
in salt-sensitive persons, reducing urinary NO metabolites (Cubeddu, Alfieri, Hoffmann,
et al., 2000).
Endothelium-dependent and endothelium-independent vascular responses have
consistently been observed to be abnormal in African Americans compared to
Caucasians (Stein, Lang, Nelson et al., 1997; Houghton, Philbin, Strogatz, et al., 2002).
There are data suggesting that the bioavailable NO, the main determinant of
endothelium-dependent vascular function, is lower in African Americans than
Caucasians despite much higher levels of endothelial nitric oxide synthase (NOS)
activity in the former (Malinski, 2005). It appears that the synthesis of oxygen radicals,
mostly via uncoupled endothelial nitric oxide synthase (eNOS) and to a smaller degree
via NADPH oxidase, raises levels of oxidative stress, accelerates NO destruction, and
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therefore leads to reduced NO bioavailability in African Americans (Malinski, 2005), and
thus a rise in blood pressure. The section below describes the pathophysiology of each
mediator in the proposed mechanism involving the sodium-induced effect of DDAH
activity in the cascade.of sodium-induced reduction in nitric oxide and elevation in
arterial pressure in African Americans.
Nitric Oxide Synthesis
The major endothelium-derived vasoactive mediator is nitric oxide, an
endogenous messenger molecule formed in healthy vascular endothelium from the
amino acid precursor L-arginine. Endothelium-derived nitric oxide (EDNO) regulates
arterial tone through a dilator action on vascular smooth muscle cells that depends on
soluble guanylyl cyclase activation and consequent increase in intracellular cyclic 3'5'guanosine monophospate (cGMP). Reduced NO synthesis or increased inactivation
likely plays an important role in increasing vascular tone, contributing to increased
arterial resistance.

The uncoupling of eNOS from its cofactors through relative L-

arginine deficiency as well as by reduced tetrahydropterin, causes eNOS to produce
reactive oxygen species (ROS) rather than NO, thereby reducing NO synthesis (Bevers,
Braam, Post, et al., 2006) and increasing oxidative stress.

Nitric oxide inactivation

owing to excess generation of reactive oxygen species, increased production of
endogenous vasoconstrictors such as angiotensin-II and endothelin, decreased
bioavailability of L-arginine, as well as defects in intracellular transduction pathways are
several proposed mechanisms implicated in the pathophysiology of hypertension
(Gokce, Keaney, Vita, 1998).

Lerman and colleagues demonstrated that after 6

months of oral l-arginine supplementation, endothelium-dependent coronary blood flow
reserve increased by 149% in response to acetylcholine when compared to placebo
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group (Lerman, Burnett, Higano, et al., 1998).

Importantly, this improvement

establishes a link between l-arginine at high doses and improved endothelial function
that is almost entirely dependent on NO (even though it was not measured). Relative larginine deficiency is a known contributor to eNOS uncoupling.
Nitric Oxide Metabolism
Asymmetric Dimethylarginine (ADMA)
A growing body of evidence indicates that in vivo accumulation of endogenous
competitive nitric oxide synthase (NOS) inhibitors may reach sufficiently high
concentrations under pathological disease conditions to shift the enzymatic milieu to
disrupt synthesis of NO from L-arginine. An important mechanism of NO antagonism is
through asymmetric dimethylarginine (ADMA)—generated from posttranslational
modification

of

arginine

residues,

which

inhibits

NO

formation.

Asymmetric

dimethylarginine is one of three circulating endogenous analogues of L-arginine
synthesized by methylation of arginine residues catalyzed by a group of enzymes
termed protein arginine N-methyltransferases (PRMTs). The other two methylarginines
include N(G)-monomethyl-L-arginine (L-NMMA), which has low in vivo circulating levels,
and symmetric dimethylarginine (SDMA) which does not inhibit NOS and is not
hydrolyzed by dimethylarginine dimethylaminohydrolase (DDAH) enzyme (Figure 2).
As the principal endogenous inhibitor of nitric oxide synthase, ADMA is an
important regulator of NO formation. Most NO deficient states are not characterized by
low NO production but rather by high oxidative stress and high NO destruction rates.
Increased ADMA levels correlate with disease severity in patients with peripheral
arterial disease, and are linked to increased cardiovascular risk (Boger, Bode-Boger,
Szuba, et al., 1998; Cooke, 2000). ADMA levels are elevated in hypercholesterolemia,
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hyperhomocysteinemia, diabetes mellitus, peripheral arterial occlusive disease,
hypertension, chronic heart failure, coronary artery disease, pregnancy-induced
hypertension and preeclampsia, erectile dysfunction, renal disease, as well as other
clinical conditions (Lundman, Eriksson, Stuhlinger, et al., 2001; Boger, Bode-Boger,
Thiele, et al., 1997; Kielstein, Boger, Bode-Boger, et al., 1999; Abbasi, Asagmi, Cooke,
et al., 2001; Usui, Matsuoka, Miyazaki, et al., 1998; Surdacki, Nowicki, Sandmann, et
al., 1999; Pettersson, Hedner, Milsom, et al., 1998).

ADMA also causes local

vasoconstriction when infused intra-arterially, and increases systemic vascular
resistance and impairs renal function when infused systemically (Figure 3).

More

recently, Melikian and colleagues found that ADMA was the only independent correlate
(inverse) of endothelial function and in a multivariable regression analysis race was the
only independent determinant/correlate of plasma ADMA levels. Healthy Black African
men had approximately 33% higher ADMA levels in comparison with White European
men (Melikian, Wheatcroft, Ogah, et al., 2007). Also in healthy, young, normotensive
Black African men, flow-mediated dilatation was significantly depressed when compared
to White European men (5.2 ± 0.3 and 6.3 ± 0.4; p=0.02, respectively).

Figure 2. Structure of l-arginine and endogenous methylarginines, N(G)-monomethyl-Larginine (L-NMMA), asymmetric dimethylarginine (ADMA) and symmetric
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Figure 3. Schematic representation of the pathophysiological sequelae of elevated
ADMA levels. Reference: Rainer H. Boger M.D., Professor and Head, Clinical
Pharmacology Unit, Institute of Experimental and Clinical Pharmacology.
In salt-sensitive animal and human studies of hypertension, ADMA level
correlates closely with elevation in arterial pressure (Matsuoka, Itoh, Kimoto, et al.,
1997).

More direct evidence that ADMA has a role in modulating cardiovascular

hemodynamics was provided by Kielstein and colleagues (Kielstein, Impraim, Simmel,
2004), who conducted a series of controlled experiments with graded intravenous
infusions of ADMA in healthy individuals. Evidence indicated that acute increases in
plasma ADMA within a physiologically relevant range (2-10 mol/L) affected the
cardiovascular system in healthy human subjects in vivo resulting in a sustained
reduction in cardiac output, marked increase in mean arterial pressure, and systemicand reno- vascular resistance, as well as a decrease in effective renal plasma flow.
During ADMA infusion, Kielstein and colleagues also noted a significant reduction in
concentrations of plasma cGMP, the main second messenger of NO (Kielstein,
Impraim, Simmel, 2004). Moreover, ADMA infusion caused significant sodium retention
and an increase in blood pressure (BP) via a decrease in renal sodium excretion.
Recently, Fang and colleagues (2006) demonstrated that high-salt significantly raises
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plasma ADMA and BP while decreasing plasma NO synthesis and urinary NO excretion
in normotensive salt-sensitive Asians after salt loading but not in the salt-resistant
subjects. (Fang, Mu, He, et al., 2006). This finding suggests that salt loading inhibits
NO synthesis by increasing the production of ADMA in salt-sensitive subjects.
Furthermore, potassium supplementation attenuated the effects of the high-salt diet on
plasma ADMA, NO level, urinary NO excretion, and BP in normotensive salt- sensitive
Asians; supplementing salt sensitive normotensive African Americans with potassium
bicarbonate also has been shown to ameliorate salt sensitivity in a dose-dependent
manner (Morris, Sebastian, Forman, et al., 1999). The data in Asians suggest that
potassium supplementation in normotensive salt- sensitive subjects prevents sodiuminduced depression in NO by preventing the salt-induced rise in ADMA. The data in
both Asians and African Americans demonstrate that potassium supplementation
ameliorates the salt-induced rise in BP.
In a nested, case-control study involving 150 middle-aged, non-smoking men,
high ADMA levels were associated with a 3.9-fold elevated risk for acute coronary
events (Valkonen, Paiva, Salonen, et al., 2001). ADMA is a competitive inhibitor of
eNOS and its inhibitory action can be overcome by increasing the concentration of the
enzyme's substrate, L-arginine. Circulating L-arginine concentrations have been found
to be within the normal range in most clinical conditions associated with endothelial
dysfunction.

Few patients experience pathologically low L-arginine concentrations.

However, clinical and experimental evidence suggests that chronic elevation of ADMA
causes relative L-arginine deficiency, even in the presence of "normal" L-arginine levels.
These findings collectively suggest that chronic elevation of plasma ADMA acts as a
modulator of vascular physiology under certain conditions.
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Dimethylarginine Dimethylaminohydrolase (DDAH)
Dimethylarginine dimethylaminohydrolase is an enzyme which converts ADMA
into

citrulline

and

dimethylamine

(Ogawa,

Kimoto,

Sasaoka,

1987)

[DDAHADMACitrulline+Dimethylamine] (Figure 4). Although, plasma asymmetric
dimethylarginine is partially cleared by the kidneys, the vast majority of ADMA is
degraded by DDAH. Of the total daily production of ADMA in humans, only 10% is
excreted unchanged by the kidneys and the remaining 90% is metabolized by DDAH
(Wilcken, Sim, Wang, et al., 2007).

The activity of DDAH is impaired by oxidative

stress, which permits ADMA to accumulate.

A wide range of pathological stimuli

induces endothelial oxidative stress such as oxidized low-density lipoprotein cholesterol,
high

dietary

salt

intake,

inflammatory

cytokines,

hyperglycemia,

and

hyperhomocystinemia. The attenuated activity of DDAH allows ADMA levels to rise
thereby blocking NO production.

Figure 4. Simplified scheme showing the main metabolic pathways for asymmetric
dimethylarginine (ADMA). DDAH, dimethylarginine dimethylaminohydrolase; DMA,
dimethylamine. (Baylis, 2008)
Collectively, the ADMA-DDAH system appears to be involved in regulation of
endogenous NO synthesis.

Firstly, Tojo and colleagues demonstrated that male
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Sprague-Dawley

rats

on

a

low

sodium

diet

had

a

significantly

enhanced

immunohistochemical expression of eNOS in renal vascular endothelium as well as
enhanced DDAH renal expression as compared to high sodium rats.

Secondly, in

erythropoietin (EPO)-induced hypertension, the postulated mechanism of elevated BP
involves enhanced vascular reactivity and vasoconstriction. Scalera and colleagues
incubated endothelial cells for 24 hours in the presence of EPO, and analyzed
measures of reactive oxygen species (ROS), ADMA, and activity of DDAH. They found
that after endothelial cells were exposed to EPO, ADMA concentration significantly
increased in a dose-dependent manner versus control and was accompanied by a
significant reduction in NO synthesis and an increase in oxidative stress, as measured
by intracellular ROS. Furthermore, addition of antioxidant (pyrrolidine dithiocarbamate)
preserved DDAH activity and reduced ADMA accumulation. In summary, these studies
support the idea that sodium influences NO metabolism in a manner consistent with
raising levels of oxidative stress and DDAH activity appears to be sensitive to oxidative
stress. However, it remains unclear if sodium-induced changes in oxidative stress can
actually be linked to downregulation of DDAH in humans.
Nitric Oxide Homeostasis
Reactive Oxygen Species, Superoxide Dismutase, and NADPH Oxidase
Superoxide anion (O2–) and other ROS are constant products of cellular
metabolism.

However, the development of oxidative stress is determined by the

balance between the production of ROS such as O2– mainly by NADPH oxidase
(Taylor, Glocka, Liang, et al., 2006) and degradation by the antioxidant defense system
involving superoxide dismutase (SOD). Superoxide is usually instantly reduced by the
enzyme SOD normally present in living tissues (Kitiyakara, Chabrashvili, Chen, et al.,
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2003). Scavenging of O2– significantly reduces BP in several experimental models of
hypertension (Schnackenberg, Welch, Wilcox, 1998; Welch, Blau, Xie, 2005), especially
those associated with salt sensitivity (Manning, Meng, Tian, 2003; Howard, Patterson,
Mullins, et al., 2005). Additionally, superoxide dismutase helps preserve the activity of
NO by scavenging O2–, thus increasing the half-life of NO. The mechanism for NO
degradation in blood vessels is its interaction with O2–, leading to the formation of
peroxynitrite (Jung, Marklund, Xia, et al., 2007). Previous studies have indicated that
inhibition of NO generation during high-salt intake leads to the development of saltsensitive hypertension and the impairment of kidney function (Tolins, Shultz, 1994;
Yamada, Sassaki, Fujihara, 1996; Nakanishi, Hara, Nagai, 2002). Thus, increases in
oxidative stress as evidence by increased O2– level resulting in NO deficiency appear to
contribute to the development of salt sensitivity.
The exact mechanism whereby the endogenous level of O2– is increased during
NOS inhibition is not yet clear. The uncoupling of eNOS from its cofactors causes
eNOS to produce O2– instead of NO. A recent study by Taylor and colleagues (2006)
found that excess renal medullary interstitial superoxide production in salt-sensitive rats
contributed to salt-induced hypertension, and that NADPH oxidase was the major
source of the excess superoxide.

By administering a NADPH oxidase inhibitor,

apocynin, there was a reduction in medullary interstitial superoxide as well as mean
arterial pressure in salt-sensitive rats.

Both NO and O2– are constant products of

cellular metabolism, and both of these molecules are constantly interacting with each
other in biological tissues (Modlinger, Wilcox, Aslam, 2004). Normally, O2– in the tissue
is kept to a minimal level by the antioxidative function of SOD. However, when NO
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production is diminished in the tissue or when eNOS uncouples generating ROS instead
of NO, it is expected that this balance may be altered allowing O2– accumulation in the
tissue (Majid, Nishiyama, Jackson, 2004).
In a study by Meng and colleagues, a 3-week intravenous infusion of Tempol, a
membrane-permeable SOD mimetic, markedly blunted the salt-induced increase in
arterial pressure in Dahl salt-sensitive rats by approximately 22 mm Hg (Meng, Cason
Gannon, et al., 2003).

Superoxide anion release was significantly higher in salt

sensitive high-sodium rats compared with salt sensitive low-sodium rats, suggesting that
a high sodium intake in salt-sensitive rats causes increased oxidative stress. Tempol
markedly decreased O2– release in the renal cortex and medulla, and the magnitude of
the reduction of O2– release by Tempol was significantly greater in salt sensitive highsodium rats. Moreover, Tempol infusion in the Dhal salt-sensitive rats on a high salt
diet delayed the onset and reduced the magnitude of HTN. However, the mechanism of
the amelioration of hypertension in the high-sodium/Tempol salt-sensitive rats was not
clear.
Schnackenberg and colleagues previously showed that an acute bolus injection
of Tempol reduced arterial pressure and renal vascular resistance in the spontaneous
hypertensive rat (SHR) but not the Wistar-Kyoto rat and that this response was blocked
by nitro-L-arginine methyl ester, an inhibitor of NO synthases, but not by
norepinephrine. This implies that Tempol might prevent inactivation of NO by O2–, thus
increasing

the

bioavailability

of

NO

(Schnackenberg,

Welch,

Wilcox,

1998).

Furthermore, salt loading induces oxidative stress in the kidneys of normal rats;
Kitiyakara and colleagues reported that the increased oxidative stress during high salt
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was accompanied by increased NADPH oxidase activity and decreased renal
expression of the mRNA for intracellular and mitochondrial SOD. Overall, there seems
to be a delicate balance between the production and destruction of O2– with NO
bioactivity.
All mammalian tissue contains three forms of superoxide dismutase (SOD),
differing primarily in their locations (Beyer, Imlay, and Fridovich, 1991).

SOD-1 is

localized in the cytosol, SOD-2 in the mitochondria, and SOD-3 in the extracellular
space. Importantly, extracelluar SOD-3 activity is ~100-fold higher in the vessel wall
than in other tissues. Thus, in the vessel wall, SOD-3 plays a critical role in regulating
the vascular re-dox state in the extracellular space.

Strålin and colleagues,

demonstrated that SOD-3 is a very important component of the total superoxide
dismutase in the vessel wall, comprising one-third to one-half of the total vascular SOD
activity (Strålin, Karlsson, Johansson, et al., 1995). Additionally, the predominant site of
production of SOD-3 is the smooth muscle cell in healthy vessels. Thus, an important
function of extracellular SOD-3 in the arterial wall may be the preservation of bioactivity
of NO with its antiatherogenic and vasodilating effects. In support of this, Jung and
colleagues revealed that a shortage of endogenous vascular extracellular SOD activity
occurs in situations of combined oxidative and nitrosative stress (Jung, Marklund, Xia,
et al., 2007).
Reactive Oxygen Species and Dimethylarginine Dimethylaminohydrolase
Oxidative stress by S-nitrosylation (presence of a reactive cysteine residue in the
active site of DDAH) inactivates DDAH (Leiper, Murray-Rust, McDonald, et al., 2002),
which provides an important mechanism leading to upregulation in the levels of ADMA,
thereby limiting further NO generation. Isoprostanes are prostaglandin-like substances
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that are produced in vivo independently of cyclooxygenase enzymes, primarily by free
radical-induced peroxidation of arachidonic acid. Isoprostanes have been shown to be
extremely accurate markers of oxidative stress in vivo, as isoprostane levels increase
dramatically in experimental animal models of oxidant injury and these levels can be
suppressed by administration of antioxidants (Morrow, Roberts, 1996). Environments
which

elevate

intracellular

oxidative

stress

including

hyperglycemia

and

hyperhomocysteinemia have also demonstrated impaired activity of DDAH (Lin, Ito,
Asagami, et al., 2002; Stuhlinger, Tsao, Her, et al., 2001). On the other hand, several
antioxidants (i.e., all-trans-Retinoic acid, polyethylene glycol-conjugated SOD [PEGSOD]) increased expression of DDAH, thus DDAH is considered an oxidant-sensitive
enzyme (Achan, Tran, Arrigoni et al., 2002; Lin, Ito, Asagami, et al., 2002).
Nitric Oxide and Natriuresis
In Dahl salt-sensitive rats, sodium chloride loading induces endothelial
dysfunction and hypertension, whereas BP and vasodilator responses remain normal
when these animals consume a low-salt diet. In this animal model of hypertension, Larginine prevents the development of hypertension, and this protection can be
overcome by an inhibitor of NOS (Chen and Sanders, 1991). It is now understood that
renovascular NO production modulates salt and water excretion, and that salt-sensitive
hypertension may reflect an impairment of NO action (Shultz and Tolins, 1993). In
humans, the fall in pressure with L-arginine administration is more pronounced in saltsensitive subjects (Campese, Amar, Anjali, et al., 1997). From a clinical perspective,
these findings strongly suggest that L-arginine exerts a significant hypotensive effect in
patients who manifest salt sensitivity, presumably via augmentation of NO production.
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Obesity
In all likelihood, obesity contributes significantly to HTN risk in all racial/ethnic
populations, and many racial and ethnic minorities manifest obesity disproportionately.
Approximately 80% of people with HTN in the United States are overweight or obese
(BMI ≥ 25 kg/m2). In Black women the prevalence of extreme obesity (BMI > 40 kg/m2)
is almost 1 in 6, a prevalence that is ~3 – 4-fold higher than that of White and Hispanic
women (Hensrud, Klein, 2006). There are marked ethnic and age-based differences in
the rates of weight accumulation.

Relative to White women the onset of obesity

occurred sooner for Black and Hispanic women. After 28 years of age, Black men
develop obesity more rapidly than White men.

Anthropometric measures, such as

obesity, especially in women, can also influence biologic systems involved in BP
regulation and the expression of pressure-related target-organ damage (i.e. chronic
renal injury). For example, obesity is a major anthropometric correlate of salt sensitivity
in Blacks and Whites (Flack, Ensrud, Mascioli, et al., 1991).
Vascular Stiffness
Blood pressure represents the confluence of vascular properties such as arterial
stiffness, endothelial dysfunction, cardiac output, peripheral vascular resistance and
extracellular/intravascular volume.

Blood pressure is a function of blood flow and

vascular resistance (i.e., BP= cardiac output x total peripheral resistance). In clinical
practice, pressure is defined in terms of systolic (SBP) and diastolic (DBP) blood
pressure, which refers to a pulsatile phenomenon, with SBP and DBP representing the
extremes of the blood pressure oscillation around a mean BP value.

These are

quantitative measures of blood pressure, however, blood pressure and flow fluctuate
during the cardiac cycle. The elastic and geometric properties of the arteries cause the

20
arterial pressure pulse to change its shape as it travels along the arterial tree. Thus,
hemodynamic information contained in the shape of the arterial pressure pulse reflects
the type of interaction between the heart as a pump and the arterial system as the load,
and can complement the conventional measurement of BP.
Arterial stiffness is an important determinant of cardiovascular risk, and the
augmentation index is a measure of systemic arterial stiffness derived from the
ascending aortic pressure waveform. In normal individuals the reflected wave returns to
the central aorta late in diastole (augmenting coronary flow which occurs solely in
diastole) and thus there is relatively little amplification of the aortic pressure. As blood
vessels become stiff due to age-related processes, and/or other co-morbidities, such as
hypertension, hyperlipidemia, diabetes mellitus, and peripheral vascular diseases, the
pulse wave is transmitted more rapidly and returns to the heart during systole, resulting
in a greater augmentation of the central aortic systolic pressure (Gatzka, Cameron,
Kingwell, et al., 1998; Wilkinson, Prasad, Hall, et al., 2002).
Theoretical Framework
Based on the review of literature, a plausible physiologic model is presented
(Figure 1) to explain the relationship between sodium intake and nitric oxide activity
resulting in salt sensitive increases in blood pressure.
Summary of Literature
Epidemiological and clinical studies demonstrated a clear relationship between
salt intake and hypertension. However, the BP response to changes in dietary salt are
heterogeneous among individuals. Dietary sodium raises oxidative stress and reactive
oxygen species contribute to impaired endothelial function in salt-sensitive rats (Zhou,
et al., 2003, Laffer et al., 2006). The activity of DDAH is impaired by oxidative stress
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(Leiper, Murray-Rust, McDonald, et al., 2002), thus permitting ADMA to accumulate and
resulting in the inhibition of NO. Although it is known that sodium stimulates oxidative
stress and modulates the renin-angiotensin system, in both humans and rats; it is
currently unknown whether dietary sodium has an effect on DDAH activity.

The

purpose of this study is to investigate and assess if there is a sodium-induced effect on
DDAH activity which would represent a plausible mechanism in human salt sensitivity.
Purpose and Aims
The purpose of this study is to test the hypothesized physiologic model to
determine the mechanism involved in sodium-induced depression of NO synthesis and
elevation in blood pressure in African American individuals. Three specific aims will be
tested.
Specific Aims:
Aim 1: Determine the correlation between DDAH activity, levels of ADMA, and urinary
NO metabolites following dietary salt loading.
Hypothesis 1a: Dietary salt loading correlates with a reduction in DDAH activity
(urine dimethylamine [DMA]:urine asymmetrical dimethylarginine [ADMA],
is used as a marker of DDAH activity/expression; GC-Mass Spec).
Hypothesis 1b: A reduction in DDAH activity correlates with a rise in ADMA
(urine ADMA; GC-Mass Spec) levels, and subsequent reductions in
urinary levels of NO metabolites following dietary salt loading.
Aim 2: Determine the dietary sodium-induced changes in DDAH activity, circulating
levels of ADMA, and NO metabolites, and their relationship to changes in arterial
stiffness (AS) and blood pressure (BP) following dietary salt loading.
Hypothesis 2: Dietary salt loading correlates with a reduction in DDAH activity
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and an increase in ADMA levels and a reduction in NO metabolites
resulting in an increase in AS (SphygmoCor) and BP (cuff).
Aim 3: Determine the association between DDAH activity and ADMA levels and their
correlation with the presence of the gene polymorphism (superoxide dismutase-3 [SOD3]), circulating markers of oxidative stress, and free radical following dietary salt loading.
Hypothesis 3:

Dietary salt loading correlates with increased measures of

oxidative stress (total 8-isoprostanes) and free radical (nitrotyrosine) and a
reduction in DDAH activity and increase in ADMA levels, with these
sodium-induced changes being greatest in subjects without the SOD-3
genotype.

23
CHAPTER 3
METHODS
Design
The study used an integral cross-over experimental design with four-phases
lasting 20 weeks. The current study was a sub-study associated with an ongoing NIHtrial “Obesity, Nitiric Oxide, and Salt Sensitivity” (ONOSS) (NIH/NIEHS 1P50ES01239501). Healthy, normotensive African American men and women from the ongoing NIHtrial ONOSS were used as the population study sample. The ONOSS study was a 39week study of healthy African American men and women aged 35 years and older who
were overweight or obese [body mass index (BMI) > 25 and < 40 kg/m2].
Sample
Overall, 210 African American participants were recruited to the ONOSS study
from 14 metro-Detroit community sites to participate in the study, and the data were
collected between 2004-2008. The recruitment strategies used included local health
fairs, bus advertisements, and radio spots. This study was reviewed and approved by
the Wayne State University, Institutional Review Board and signed informed consent
was obtained from all participants prior to their participation.
To be included in the overall study, participants needed to be normotensive,
African American men and women aged 35 years and older with non-hypertensive BP
levels based on average cuff BP readings at the third eligibility visit and who were
overweight or obese with a BMI of ≥ 25 and < 40 kg/m2, with the urinary
sodium:creatinine ≤ 1.1 at the third eligibility visit. The exclusion criteria included the
following: hypertension according to JNC VI co-morbidity definitions > 140/90 mm Hg, if
there was kidney disease [estimated glomerular filtration rate (GFR) < 60 mL/min/1.73
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m2], or diabetes mellitus [fasting blood sugar (BS) > 126 or take diabetes medication or
random BS > 200 mg/dl], psychiatric illness or dementia, heart failure, angina pectoris,
intermittent claudication, valvular heart disease, myocardial infarction, coronary artery
bypass graft, coronary or peripheral angioplasty, history of life threatening cardiac
arrhythmias, peripheral vascular surgery within the past 6 months, use of non-steroidal
anti-inflammatory drugs > 4 days/week, liver function tests > 1.5 x upper normal,
albumin < 3.5, planned to move > 50 miles or travel extensively from the area during the
next 12 months, urine albumin:creatinine ratio > 500, night-shift work, use of
supplemental vitamins/minerals/herbs, any difficulty swallowing, or positive pregnancy
test (given to premenopausal women who have not had a hysterectomy and have not
been surgically sterilized). They were also excluded if currently taking cardiovascular
medications including lipid lowering drugs, medications for mental illness, > 3 alcoholic
drinks per day, > 6 restaurant meals per week, oral steroids or nitrates, or if they
refused to sign informed consent form, refused venipuncture, refused to comply with
overnight urine collections, and refused to take study capsules.
Of the original 72 participants recruited in the sub-study, 63 participants were
included at baseline visit, and only 43 participants were included in the analyses after
application of exclusion criteria and participant drop outs. The population consisted of
normotensive (BP < 140/90 mm Hg), overweight (body mass index = 25 – 39.9 kg/m2)
African American men and women aged 35 years and older.

The majority of

participants were female (87%) and the mean age was 45 years.
Study Protocol
The current sub-study was conducted in four phases (Figure 5, Table 1) and
incorporated a randomized, blinded cross-over design. In Phase I: Dietary Orientation,
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a low-sodium plus weight maintenance dietary regimen was introduced for each
participant during the initial 8 weeks of the study, representing the pre-randomization
phase. A registered dietitian counseled each participant at their initial visit and follow-up
clinic visits where she advised participants to maintain a food diary; and weekly followup telephone encounters were completed on each participant throughout the remaining
time of the study. Participant vital signs (i.e., blood pressure, pulse rate, and weight)
were measured every other week.

In Phase II: Randomization, participants were

randomized to either a 4-week placebo or a 100 mmol sodium loaded diet [1,800
grams]. During the blinded 4-week salt loading period, participants received sodium
chloride capsules that contained 11.1 mmol of sodium [placebo was an inactive
ingredient]. Participants took 3 capsules three times a day during sodium and placebo
supplementation. Participants were encouraged to take their capsules with food. At the
end of the 4th week, lab samples and measurements were obtained and represented the
post-randomization phase of either placebo or sodium exposure. Participants continued
the low-sodium diet during the treatment period with maintenance of body weight
achieved.

Intakes of potassium and calcium were as expected to be, close to the

average for older African Americans in the US population (54 mmol/day potassium and
550 mg/day calcium) (Kant, Graubard, Kumanyika, 2007). In Phase III Wash-out, all
participants underwent a wash-out period during the ensuing 4 weeks.

Participant

blood pressure, pulse rate, and weight were measured every other week, and they
continued to undergo dietary counseling. In Phase IV: Cross-over, participants were
randomized to either the 4-week remaining placebo or 100 mmol sodium loaded diet.
At the end of the 20th week (final visit), lab samples and measurements were obtained
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and represented the post-randomization phase of either the remaining placebo or
sodium exposure.
Throughout the study, participants continued the low-sodium diet during the
intervention period with maintenance of body weight.

Compliance to the diet and

treatment capsules were monitored by determining the urinary sodium:creatinine ratio in
three pooled overnight urine samples, once before the sodium/placebo supplementation
in Phase II and twice thereafter, following the sodium and placebo loading.
The choice of a study design that manipulates a single dietary nutrient, sodium
chloride, on the background of a fixed dietary intake that is typical of free-living
individuals, is purposeful. Studies like the DASH diet intervention (Milan, Mulatero,
Rabbia, et al., 2002; Volmer, Sacks, Ard, et al., 2001) have demonstrated that
simultaneously changing multiple dietary nutrients is an effective means of lowering BP.
A DASH-like design is, however, less well suited for understanding the physiological
effect of a single dietary nutrient. Thus, we have chosen to hold constant, as best we
can, potential modifiers of the salt-BP response (e.g., potassium, calcium, fat) and to
discern the impact of physiological modifiers and mediators of the BP response to
dietary sodium. The chosen population, African Americans, have a high prevalence of
nitric oxide deficiency, obesity, salt sensitivity, and endothelial dysfunction (Winkleby,
Kraemer, Ahn, et al., 1998; Flack, Grimm, Staffileno, et al., 2002).
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Phase I: Dietary Orientation
8 Weeks
Phase II:
Randomization
100 mmol Sodium
Supplementation

Placebo
Supplementation
4 Weeks

Phase III:
Wash-Out
4 Weeks
Phase IV:
Crossover
4 Weeks
100 mmol Sodium
Supplementation

Placebo
Supplementation

Figure 5. Four-Phase Protocol Design This flow diagram represents the cross-over
design used in the current sub-study for 20 weeks. During Phase I, participants
underwent 8 weeks of dietary orientation to a low-sodium plus weight maintenance diet.
This dietary regimen was continued throughout all of the phases of the study. Phase II
occurred after the initial 8 weeks of dietary orientation, where participants were blindly
randomized to either the placebo or sodium supplementation cohort for the following 4
weeks. Next, all participants underwent a Phase III wash-out period for 4 more weeks,
prior to the final phase IV cross-over phase where participants were crossed-over into
the remaining cohort, either placebo or sodium supplementation. The final visit for this
sub-study was at the end of the phase IV randomization placebo/sodium
supplementation, representing the end of the 20th week. This protocol followed a
randomized cross-over design to control for time and order effects.
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Table 1. Protocol for Four-Phase Sub-Study
PERIODS FOR ANALYSIS

Phase I: Low
Sodium Diet

Phase II: Placebo/Sodium

Phase III: Wash-Out

Phase IV:
Placebo/Sodium

Week

0--7

8

13

17

Vitals/BMI

X (every other visit)

X

X

Ambulatory BP

X

X

Dietary Assessment

X

Physical Activity

X

9

10

11

12

14

15

X

16

18

19

X

20
X
X
X

X

X

Asymmetric
dimethylarginine

X

X

Dimethylarginine
dimethylaminohydrolase

X

X

Plasma Isoprostanes

X

X

X

Urinary Nitric Oxide

X

X

X

Free Radicals

X

X

X

Overnight Urinary Na, K,
Creatinine

X

X

X

Platelet Nitric Oxide
Generation

X

X

X

Pulse Wave Velocity

X

X

X

Dispense study capsules
OR broth

X

X

Collect study capsules

X

X

Clinic Visit

X (every other visit)

Phone visit /Dietary
Counseling

X (every other visit)

X

X

X
X

X

X

X
X

X
X

X
X

X

X

This chart details all visits and explicitly describes the protocol for this sub-study. Under each visit
phase lists the lab/measures, or data which is to be collected for each successive visit through all four
phases of the 20-week study.

Study Measures
1) Dietary Intake Assessment: Dietary assessments were completed by the registered
dietitian once before the sodium/placebo supplementation began in Phase II and at
the end of the final visit (end of 20th week). Dietary data is thought to be underreported in obese subjects (Kretsch, Fong, Green, et al., 1999). The records were
analyzed with the Nutrition Data System, research version of the software
(University of Minnesota, Nutrition Coordinating Center). At the beginning and end
of the study, a Food Frequency Questionnaire (Block’98 Food Frequency
Questionnaire) was also administered to capture usual eating patterns over the last
12 months (Block, Woods, Potosky, et al., 1990). The intake of electrolytes was
estimated (e.g. calcium, potassium, and magnesium).
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2) High Dietary Sodium: During the blinded 4-week salt loading period, participants
received sodium chloride capsules that contained 11.1 mmol of sodium [placebo
was an inactive ingredient]. Participants took 3 capsules three times a day during
sodium and placebo supplementation.
3) Reactive Oxygen Species is measured using two variables: Total 8-isoprostanes
and free radicals
Total 8-Isoprostanes: 8-Isoprostane level in serum appears to be a good marker of
oxidative stress in humans, and immunoassays for these oxidation products are
suggested to be more specific than chromatographic methods (Proudfoot, Barden,
Mori, et al., 1999).

Only total 8-isoprostane was measured because free 8-

isoprostane determination requires much larger sample volumes due to its low levels
and there was excellent correlation between total and free 8-isoprostane in plasma.
Total 8-isoprostane is expected to be a good measure of lipid peroxidation levels,
based on published data from human studies (Proudfoot, Barden, Mori, et al., 1999;
Morrow, Frei, Longmire, et al., 1995). Total 8-isoprostane levels in plasma were
measured only once at baseline. Total 8-isoprostane plasma levels were measured
using an EIA kit from Cayman Chemical Co. (Ann Arbor, MI) using a modified SepPak procedure.
Free Radical:

Free radical was measured once before the sodium/placebo

supplementation in Phase II, considered a baseline value. The type of free radical
generated in the arterial wall was estimated from quantization of nitrotyrosine.
These protein degradation products are generated from nitric oxide, hydroxyl radical
and hypochlorous acid, respectively.

Nitrotyrosine was quantified by gas

chromatography with mass spectral detection (GC/MS). It has been proposed that
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assay of oxidized amino acids such as tyrosine in plasma may be a marker of
oxidative stress relevant to cardiovascular diseases (Heinecke, 2002). Free radicals
are critical to the interpretation of the study results because they destroy NO. Also
joint consideration of free radical and NO production will permit characterization of
the impact of the relative balance between desirable NO and mostly undesirable free
radical generation on BP responses to dietary sodium manipulations.
4) Superoxide Dismutase (SOD): The 47C>T(A16V) polymorphism in SOD2 has been
identified as functional. Accordingly, it is linked to a 30-40% decrease in enzyme
activity. The 637 C>G (Arg213Gly) mutation in SOD3 has been linked to an 8-10
fold increase in enzyme activity. SOD is an antioxidant enzyme, thus increased and
reduced activity is, respectively, associated with greater and lesser anti-oxidant
effects. The latter would lead to higher levels of oxidative stress.
5) Dimethylarginine dimethylaminohydrolase (DDAH):

DDAH activity was indirectly

measured by the quantification of endogenous dimethlyamine (DMA), product of
degraded ADMA by DDAH enzyme, and ADMA (DMA/ADMA molar ratio index for
creatinine, micromol/mmol creatinine) (Chobanyan, Thum, Suchy, et al., 2007).
Urine DMA was measured twice during the sub-study after the dietary sodium and
placebo supplementation phases, simultaneously with ADMA. Urine biomonitoring
data was adjusted to the constant creatinine concentration to correct for variable
dilutions among spot samples.

Dimethlyamine in human urine by gas

chromatography-mass spectrometry (GC-MS) was determined by the Institute for
Clinical Pharmacology, Hannover Medical School, Hannover, Germany.
6) Asymmetric dimethylarginine (ADMA):

ADMA levels fall as DDAH levels rise.

ADMA was measured twice during the study, after dietary sodium and placebo
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supplementation (end of the placebo phase represents the “baseline” ADMA level).
The ratio of urine ADMA to urine creatinine (ADMA/Cr) was used in the statistical
analyses to control for urine dilution, a standard method when evaluating urine
biomarkers. ADMA in human urine by GC-MS was determined by the Institute for
Clinical Pharmacology, Hannover Medical School, Hannover, Germany.
7) Urinary Nitric Oxide (NO): Urinalysis of total nitrate and nitrite concentration was
determined by the Institute for Clinical Pharmacology, Hannover Medical School,
Hannover, Germany. Total nitrate and nitrite metabolites in urine, which represents
crude nitric oxide production, were measured by first converting nitrate to nitrite
using nitrate reductase and then treating with Griess reagents to convert nitrite into a
deep purple azo compound (Tsikas, 2007).

Photometric measurement of the

absorbance of the azo compound was at 540 or 550 nm. The detection limit for
nitrate/nitrite assay (80 μl) and nitrite assay (100 μl) was 2.5 μM and 2.0 μM,
respectively, and the mean interassay CV was 3.4%. In non-contaminated urine,
nitrate would be approximately 99% of the sum of nitrate and nitrite. Total nitrate
and nitrite metabolites in urine were expressed as an excretion rate in units µmol/8
hours (Tsikas, 2007). The ratio of urine NO to urine Cr (NO/Cr) was used in the
statistical analyses to control for urine dilution, a standard method when evaluating
urine biomarkers. NO metabolites were measured once before the sodium/placebo
supplementation in Phase II and twice thereafter, following the sodium and placebo
loading. Prior to these visits, participants were counseled to adhere to a low nitrate
diet for the four days prior to the urine collection. Written materials were provided
along with telephone counseling. Urinary nitrate measures represented nitric oxide
production, a key predictor and outcome variable in this study.
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8) Obesity – height/weight- body mass index (BMI): Height was obtained at the initial
visit, while weight was measured using a standard balance beam scale. Height and
weight are necessary to determine BMI.
9) There were two outcome measures of interest: arterial stiffness and blood pressure:
Arterial Stiffness (AS):

Measurement of AS was performed once before the

sodium/placebo supplementation in Phase II and twice thereafter, following the
sodium and placebo loading.

AS was measured non-invasively using the

SphygmoCor system (AtCor Medical, Australia). AS was measured by calculating
augmentation index (AI). AS is positively correlated with AI (the difference between
the first and second pressure peaks divided by pulse pressure).

AS should be

affected by NO metabolism, oxidative stress, and/or dietary sodium manipulations.
Resting Blood Pressure: All BP measurements were obtained using a protocol that
was adapted from the American Heart Association Recommendations for Human BP
Determination (Perloff, Grim, Flack, et al., 1993). Three pressure readings were
recorded within a 5-minute period taking the average of these 3 readings to record
as the BP measurement for that visit. BP was measured at every clinic visit for all
participants, however the BP at the end of sodium and placebo periods were utilized
in the analysis. BP is the primary study response variable. Systolic blood pressure
(SBP) was chosen as the primary response variable because it is measured more
precisely than diastolic BP (DBP), and because it more closely related to targetorgan

injury

and

pressure-related

mortality,

even

measurement error, than DBP (He, et al., 1999).

after

consideration

of

Further, preliminary studies

suggest that increased dietary sodium exposure has a relatively greater impact on
SBP compared to DBP, at least on a per mm Hg basis.
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10) Urinary Sodium:Creatinine Ratio: Urinary sodium was quantified, as an estimate of
changes in dietary intake, by determining the urinary sodium:creatinine ratio in three
pooled overnight urine samples, once before the sodium/placebo supplementation in
Phase II and twice thereafter, following the sodium and placebo loading.
Statistical Analysis
Descriptive analyses for means, medians, standard deviations (SD), and 95%
confidence intervals (CI) were conducted for all continuous variables (i.e., age, body
mass index, blood pressure) while proportional distributions were examined for all
categorical variables.

Continuous variables were examined for skewness/normality

using Shapiro-Wilk statistic. Continuous data that deviate significantly from normality
were transformed to the natural logarithm to approximate a normal distribution prior to
analysis. The paired t test was used to compare the exposure effects at end of the
sodium and placebo study periods. Subsequently, Pearson correlations were utilized to
quantify associations, and were considered significant at the 5% significance level. The
outcome measures of this study were the continuous variables (DDAH, ADMA, urinary
NO metabolites, BP, and AS). The power analysis has been estimated for significance
level of 5% and showed that 66 study patients have more than 80% power for a change
in SBP. Missing data was random and participants with missing variables in regards to
the main outcome measures were eliminated from the analysis, resulting in a loss of
power. All analyses including appropriate statistics, p-values, and graphs were reported
using Statistical Analysis Software (SAS, version 9.1).
Data Analysis
Specific Aim 1:
After both dietary sodium and placebo supplementation, the relationship of the
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change in DDAH activity (urine dimethylamine [DMA]: asymmetrical dimethylarginine
[ADMA], used as a marker of DDAH activity/expression) to the change in the levels of
urinary ADMA and urinary NO metabolites, after dietary salt loading was examined.
Paired t test was used to compare the differences between the end of sodium and
placebo study periods. Pearson correlations were utilized to quantify associations, and
were considered significant at the 5% significance level. The variables were divided by
creatinine in the statistical analyses to minimize timing errors related to the collection of
the urine samples, a standard method when evaluating urine biomarkers.

The

magnitude of timing error is much less if you take the amount of sodium in
urine/creatinine in urine.

Urinary biomonitoring data are typically adjusted to the

constant creatinine concentration to correct for variable dilutions among spot samples.
Specific Aim 2:
The associations of sodium-induced changes in DDAH activity, circulating levels
of ADMA and urinary NO metabolites after dietary salt loading in relation to the changes
in BP and arterial stiffness, were quantified. Paired t test was used to compare the
differences at the end of the sodium and placebo study periods; SBP and DBP were
used separately in analyses involving BP. The variables were divided by creatinine in
the statistical analyses to minimize timing errors related to the collection of the urine
samples.
Specific Aim 3:
Levels of DDAH activity and ADMA were correlated with levels of circulating
markers of oxidative stress (total 8-isoprostanes), and free radical (nitrotyrosine) after
salt loading. Paired t test was used to compare the differences at the end of the sodium
and placebo study periods. Independent sample t test was used to compare the levels
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of oxidative stress and free radical at a given point and time between the two groups.
The variables were divided by creatinine in the statistical analyses to minimize timing
errors related to the collection of the urine samples.
Additional analyses:
There were a wide range of values in addition to a very narrowly distributed data
set, thus additional analyses utilizing z-scores was done.

These differences in

distributions made it difficult to judge similarities or significant differences among
categories in the data sets, however after standardizing with z-scores, the data results
remained relatively unchanged.
Quality Control
All persons involved in handling laboratory samples were trained in the
appropriate procedures of processing, labeling, and storage by Clandestine Laboratory
Investigators Association (CLIA) personnel standards to assure that laboratory
personnel had the appropriate training and experience to adequately perform. In order
to minimize variability of urinary nitrate/nitrite levels participants were instructed to follow
a low nitrate/nitrite diet for 4 days prior to each urinary nitrate/nitrite collection. The
mean coefficient of variation has been shown to be to be significantly higher within
individuals during a “free” diet (40 ± 9%) compared with a “low nitrate/nitrite” diet (10 ±
1%) (P = 0.02). The research staff performing BP measurements underwent periodic
training on BP measurement to verify reliability and accuracy of BP measurement
techniques. Weekly telephone contact was maintained with participants throughout a
large portion of the study to maximize the diet intervention effect and to minimize losses
to follow-up.
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Actual Difficulties and Limitations
Several (N=18) patients dropped out after the first intervention period and thus
did not receive the second treatment, while 11 participants withdrew from the overall
study.

Several patients experienced side-effects with the sodium intervention (i.e.,

nausea, swelling) which contributed to the dropout rate.

This made within-subject

comparison impossible and was particularly important as withdrawal reduced the
statistical power. This further complicated the concept of intent-to-treat analysis as
several patients randomized completed the first period, but not the second period.
Ethical Aspects
There were minimal risks to human subjects associated with the sub-study.
Some of the interview questions could be considered sensitive. No study procedures
were performed until informed consent was obtained. The Core Director ensured that
the informed consent process was appropriately carried out, reviewed the consent
forms for completeness, and ensured their confidentiality by locking them in a file in her
office. Core personnel and study personnel from each project had access to the files for
their project, but no one else could access it without the subjects’ permission.

All

procedures were performed by appropriately trained personnel according to study
protocols.

Interviewers underwent training so that they were able to perceive and

appropriately deal with any sensitivity participants may have to questionnaire items. We
did not anticipate needing medical or emergency intervention in this minimal risk study,
but there was a part-time internist and a part-time physician’s assistant assigned to the
Core, who were available by pager in addition to a hospital “code” team assigned to the
Core.

For all subjects, unique study identification numbers were utilized.

Review Board approved all aspects of the study.

Internal
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CHAPTER 4
RESULTS
Descriptive Statistics
Overall, there were no statistically significant differences in patient characteristics
at baseline in the 63 participants recruited into the sub-study; however only 43
participants were included in the analyses after application of exclusion criteria and
participant drop outs. The majority of participants were female (87%) and the mean age
was 45 years (Tables 2a and 2b).

Average measures of BP and hemodynamic

parameter did not differ by gender. Mean cuff SBP and DBP were within normal range
of SBP < 140 mmHg and DBP < 90 mmHg.
Table 2a. Baseline Patient Characteristics
Patient Characteristics
Age, years
Female, n(%)
Systolic blood pressure, mmHg
Diastolic blood pressure, mmHg
Body Mass Index, kg/m²
Current smoker, n(%)
Cholesterol, mg/dL
Triglyceride, mg/dL

Randomized Treatment Sequence
Placebo-Salt Mean (SD) Salt-Placebo Mean (SD)
45.3 (5.0)
45.9 (7.0)
28 (90%)
28 (87.5%)
116.6 (9.4)
118.6 (9.7)
76.4 (4.8)
77.6 (6.3)
32.7 (4.5)
32.0 (3.9)
3 (9.7%)
4 (12.5%)
196.1 (32.8)
206.9 (42.7)
85.3 (33.4)
93.9 (41.4)

(N=63; Placebo-Salt N=31; Salt-Placebo N=32)

Table 2b. Characteristics of Patients Included in the Crossover Analysis
Patient Characteristics
Randomized Treatment Sequence
Placebo-Salt Mean (SD) Salt-Placebo Mean (SD)
48.7 (4.4)
49.6 (7.4)
Age, years
16 (100%)
22 (91.7%)
Female, n(%)
115.5 (9.2)
120.5 (12.6)
Systolic blood pressure, mmHg
78.5 (7.0)
79.2 (7.7)
Diastolic blood pressure, mmHg
32.3 (3.9)
32.0 (4.1)
Body Mass Index, kg/m²
1 (6.25%)
2 (8.7%)
Current smoker, n(%)
188.3 (35.8)
198.8 (60.8)
Cholesterol, mg/dL
93.3 (38.0)
100.1 (40.7)
Triglyceride, mg/dL
(N=43; Placebo-Salt N=17; Salt-Placebo N=26)
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Specific Aim 1
Aim 1: Determine the correlation between DDAH activity, levels of ADMA, and urinary
NO metabolites following dietary salt loading.
Hypothesis 1a: Dietary salt loading correlates with a reduction in DDAH activity
(urine dimethylamine [DMA]:urine asymmetrical dimethylarginine [ADMA],
used as a marker of DDAH activity/expression; GC-Mass Spec).
Hypothesis 1b: A reduction in DDAH activity correlates with a rise in ADMA
(urine; GC-Mass Spec) levels, and subsequent reductions in urinary levels
of NO metabolites following dietary salt loading.
The mean of the difference between the two treatment periods (sodium –
placebo) in DDAH activity and NO metabolites was -0.83 (95% CI -2.7-1.1, SD = 4.4)
and -11.65 (95% CI -38.2-14.9, SD = 61.6), respectively, indicating that post-sodium
DDAH activity and NO metabolites tended to be slightly lower after sodium.

As

hypothesized, the DDAH activity and NO metabolite levels did decrease following
exposure to sodium supplementation, however, using paired t-test the difference
between DDAH activity and NO metabolite levels were not statistically significant
(DDAH: t = -0.87, DF = 84, p = 0.39; NO: t = -0.88, DF = 65.64, p = 0.38). The mean
DDAH:creatinine ratio following the placebo phase of the study was 13.45 (SD = 5.0);
following the sodium supplementation phase of the study the mean DDAH:creatinine
ratio was 12.62 (SD = 3.8), representing a 6.17% decrease (Figure 6). The mean
NO:creatinine ratio following the placebo phase of the study was 101.40 (SD = 76.2);
following the sodium supplementation phase of the study the mean NO:creatinine ratio
was 89.71 (SD = 42.3), representing an 11.53% decrease (Figure 7). Thus, the data
suggest but do not confirm the hypothesis that DDAH activity and NO metabolite levels
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are significantly lower after sodium supplementation.

Figure 6. DDAH:creatinine levels post-sodium and pre-sodium exposure

Figure 7. NO:creatinine levels post-sodium and pre-sodium exposure
The mean ADMA:creatinine ratio following the placebo phase of the study was
3.97 (SD = 1.4); following the sodium supplementation phase of the study the mean
ADMA:creatinine ratio was 3.81 (SD = 0.8), representing a slight 4.03% decrease
(Figure 8). The mean of the difference in ADMA:creatinine ratio was -0.164 (95% CI -

40
0.7-0.3, SD = 1.2), indicating that post-sodium ADMA:creatinine ratio tended to be
slightly lower after sodium, however using paired t-test the difference between the two
treatment periods (sodium – placebo) was not statistically significant (t = 0.64, DF =
66.9, p = 0.52).

Figure 8. ADMA:creatinine levels post-sodium and pre-sodium exposure
Pearson correlation coefficient between the difference in NO:creatinine ratio and
ADMA:creatinine ratio between the two treatment periods was positively correlated (r =
0.35; p = 0.02) (Table 3). Therefore, contrary to the initial hypothesis, ADMA was
positively associated with NO metabolite level in the urine. ADMA inhibits NO and this
inhibitory action may have stimulated NO production, however NO activity would still be
reduced because of the high ADMA activity.
Furthermore, the correlation coefficient for the difference in NO:creatinine ratio
and DDAH activity level between the two treatment periods demonstrated a strong,
positive correlation (r = 0.90; p = <0.0001).

Thus, heightened DDAH activity was

significantly associated with a greater production of NO metabolites.
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Additional analysis comparing the change in urine sodium:creatinine ratio after both
dietary sodium and placebo supplementation:
Correlation of the change in urine sodium:creatinine ratio and ADMA:creatinine
ratio between the two treatment periods was non-significant (r = 0.07; p = 0.83).
Furthermore,

the

correlation

of

the

change

in

urine

sodium:creatinine

and

DDAH:creatinine ratio (r = -0.41; p = 0.18), and urine sodium:creatinine and
NO:creatinine ratio (r= -0.37; p = 0.23) at the end of the two treatment periods were not
significant.
Table 3. Pearson Correlation Coefficients
∆NO:Creatinine
∆NO:Creatinine

1.00

∆DDAH:Creatinine

43
0.90

∆ADMA:Creatinine
∆Sodium:Creatinine

<0.0001
43
0.35
0.02
43
-0.37
0.23
12

∆DDAH:Creatinine

∆ADMA:Creatinine

∆Sodium:Creatinine

0.90
<0.0001
43
1.00

0.35
0.02
43
0.19
0.21
43

-0.37
0.23
12
-0.41
0.18
12

1.00

0.07
0.83
12
1.00

43
0.19
0.21
43
-0.41
0.18
12

43
0.07
0.83
12

12

ADMA: Asymmetric Dimethylarginine; DDAH: Dimethylarginine Dimethylaminohydrolase; NO: Nitric
Oxide

Specific Aim 2
Aim 2: Determine the dietary sodium-induced changes in DDAH activity, circulating
levels of ADMA, and NO metabolites, and their relationship to changes in arterial
stiffness (AS) and blood pressure (BP) following dietary salt loading.
Hypothesis 2: Dietary salt loading correlates with a reduction in DDAH activity
and an increase in ADMA levels and a reduction in NO metabolites
resulting in an increase in AS (SphygmoCor) and BP (cuff).
The mean of the difference in SBP and DBP respectively, was +2.8 mm Hg (95%
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CI -2.2-7.7, SD = 11.8) and +0.8 mm Hg (95% CI -2.6-4.1, SD = 7.9). As hypothesized,
the SBP and DBP levels were increased slightly following exposure to sodium
supplementation, however, using paired t-test the difference between the two SBP and
DBP levels did not reach statistical significance (SBP: t = 1.11, DF = 88, p = 0.27; DBP:
t = 0.45, DF = 88; p = 0.66) (Figure 9).

Nevertheless, the difference in

sodium:creatinine ratio was directly proportional to the difference in both SBP and DBP
between the two treatment periods (r = 0.75, p = 0.01; r = 0.49; p = 0.13, respectively);
however, SBP was the only significant correlation and it was positively associated with
the sodium:creatinine ratio; these data suggest that the magnitude of the observed BP
change was less than predicted because of a lesser between-study period change in
the urinary sodium:creatinine ratio (Table 4).

Figure 9. Blood pressure changes after sodium exposure
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Table 4. Pearson Correlation Coefficients with BP
∆SBP

∆DBP

0.18
-0.06
0.40
0.79
24
24
-0.06
-0.15
∆DDAH:Creatinine
0.76
0.48
24
24
0.03
∆ADMA:Creatinine
0.37
0.90
0.07
24
24
0.49
∆Sodium:Creatinine
0.75
0.13
0.01
11
11
ADMA: Asymmetric Dimethylarginine; DDAH: Dimethylarginine
Dimethylaminohydrolase; NO: Nitric Oxide; SBP: Systolic Blood
Pressure; DBP: Diastolic Blood Pressure
∆NO:Creatinine

Association of sodium-induced changes in ADMA:creatinine ratio after dietary salt
loading in relation to changes in BP
The difference in ADMA:creatinine ratio was also directly proportional to the
difference in SBP between the two treatment periods (r = 0.37, p = 0.07).

The

correlation between the difference in ADMA:creatinine ratio and SBP was borderline
significant.
Association of sodium-induced changes in DDAH: creatinine ratio and NO: creatinine
ratio after dietary salt loading in relation to changes in BP
The correlation between the difference in NO:creatinine ratio to the difference in
SBP and DBP between the treatment periods were non-significant (SBP: r = 0.17; p =
0.40; DBP: r = -0.06; p = 0.79.

Also, the correlation between the difference in

DDAH:creatinine ratio to the difference in SBP and DBP were also non-significant (SBP:
r = -0.06; p = 0.76; DBP: r = -0.15; p = 0.48, respectively).
Association of sodium-induced changes in arterial stiffness measures
The mean of the difference in augmentation index was +11.79 (95% CI -3.4-26.9,
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SD = 19.5), a 14.9% difference, indicating that post-sodium augmentation index tended
to be higher after sodium.

As hypothesized, the augmentation index did increase

following exposure to sodium supplementation, however, using paired t-test the
difference between the two treatment periods was suggestive though not statistically
significant (t = 1.60, DF = 26, p = 0.12).
Pearson correlation coefficient of the change in ADMA:creatinine ratio was not
significantly correlated with the change in augmentation index (r = 0.27; p = 0.42) (Table
5) between the treatment periods. On the other hand, the correlation of the change in
DDAH:creatinine ratio and the change in augmentation index between the treatment
periods was significantly negatively correlated (r = -0.61; p = 0.04). Thus, heightened
DDAH activity was strongly associated with a lower augmentation index, as the
measure of arterial stiffness, as expected. Furthermore, the change in NO:creatinine
ratio was negatively correlated with the change in augmentation index (r = -0.59; p =
0.05); thus, supporting the hypothesis that NO metabolite levels are inversely
associated with arterial stiffness.
Table 5. Pearson Correlation Coefficients with Augmentation Index
∆AI
∆NO:Creatinine
∆DDAH:Creatinine
∆ADMA:Creatinine

-0.59
0.05
11
-0.61
0.04
11
0.27
0.43
11

ADMA: Asymmetric Dimethylarginine; AI:
Augmentation Index; DDAH: Dimethylarginine
Dimethylaminohydrolase; NO: Nitric Oxide;
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Specific Aim 3
Aim 3: Determine the association between DDAH activity and ADMA levels and their
correlation with the presence of the gene polymorphism (superoxide dismutase-3 [SOD3]), circulating markers of oxidative stress, and free radical following dietary salt loading.
Hypothesis 3:

Dietary salt loading correlates with increased measures of

oxidative stress (total 8-isoprostanes) and free radical (nitrotyrosine) and a
reduction in DDAH activity and increase in ADMA levels, with these
sodium-induced changes being greatest in subjects without the SOD-3
genotype.
Nitrotyrosine and isoprostane levels were analyzed at baseline only (these
oxidative markers were not measured post-sodium, only at baseline), thus crosssectional analyses were done to determine the correlation between these oxidative
stress markers and ADMA:creatinine, DDAH:creatinine, and NO:creatinine ratio levels.
ADMA:creatinine, DDAH:creatinine, and NO:creatinine ratios were not significantly
correlated to either baseline nitrotyrosine nor isoprostane levels.
The assay for the SOD-3 polymorphism was not completed, as the Genomics
division noted that it has a very low frequency in Caucasians and even lower in African
Americans. Given our small sample size and African American population, it was
unlikely that I would find any heterogeneity.
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CHAPTER 5
Discussion
The study population was a cohort of mostly young (mean age 45 years, SD =
6.0), female (87%), African Americans who were normotensive, and overweight.
Several potentially important findings exist in this study. First of all, in a cohort of
young, overweight, African American normotensive women, the data overall trended in
the direction hypothesized. The DDAH level and NO metabolites came down after
sodium exposure, while the blood pressure rose and the augmentation index increased
by almost 12% after sodium exposure, though not statistically significant.

The

difference in sodium:creatinine ratio was directly proportional to the change in BP (SBP:
p = 0.01; DBP p = 0.13), which likely mediated the BP effect. Additionally, nitric oxide
metabolites and DDAH levels were positively correlated to each other (r = 0.90; p =
<0.0001), and changes in both DDAH and NO levels were negatively correlated to
changes in augmentation index (DDAH: r = -0.61; p = 0.04; NO: r = -0.59; p = 0.05). As
expected, after sodium loading the DDAH and NO levels decrease while the
augmentation index increases reflecting an increase in arterial stiffness.
On the other hand, the change in NO was positively correlated with the change in
ADMA (r = 0.35; p = 0.02). In speculating a physiologic pathway for this discrepancy,
ADMA inhibits NO and this inhibitory action may have stimulated NO production,
however NO activity would still be reduced because of the high ADMA activity. Thus,
the rise in NO levels would not be able to overcome the effects of ADMA inhibition.
Furthermore, the expected effect upon the oxidant-sensitive enzyme DDAH was not
detected, as there was no significant evidence of redox-sensitive inhibition of the
enzyme DDAH activity by the free radicals.

Although several studies have linked
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increased oxidative stress to high salt intake in animals (Zhou, Adam, Jaimes et al.,
2003; Tian, Moore, Braddy, et al., 2007; Swei, Lacy, DeLano, et al., 1997), the human
data are more limited. In a study by Laffer and colleagues, acute (one-day) sodium
loading and depletion using an established protocol produced corresponding increases
and decreases, respectively, in plasma F2-isoprostanes in salt sensitive hypertensive
subjects.
Citizens of acculturated societies, given free access to salt, invariably consume
between 100 and 200 mmol of sodium daily (INTERSALT, 1998).

Several meta-

analyses indicate that among hypertensive and older subjects, a 3- to 5-mm Hg systolic
and approximately 1-mm Hg diastolic change in pressure is associated with a 75 to 100
mmol/24 hour difference in sodium intake (Midgley, Matthew, Greenwood, et al., 1996;
Graudal, Galloe, Garred, 1998). The effect on younger and normotensive subjects is
less with approximately 2 to 3 mm Hg for systolic and <1 mm Hg for diastolic. Thus, this
is in line with the BP effect which occurred in our study. The major reason we likely did
not see as much physiological effect on BP and other measures was because of the
less than predicted difference in the urine sodium:creatinine ratio between the treatment
periods, as well as the smaller sample size.
On the other hand, the inability to demonstrate a strong relationship between
sodium intake and blood pressure within a population in which habitual sodium intake is
relatively generous (>120 mmol/day) does not deny such a relationship as individual
differences in susceptibility or temporal factors may influence the blood pressure
response to such intake. In other words, individuals who are susceptible to salt-induced
alterations in blood pressure may be balanced by those in whom such an effect is
negligible. Alternatively, a long period of exposure to increased sodium intake may be
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required for blood pressure manifestations to be apparent, while the age of the
population studied may influence the observations as well.

For these reasons,

information from more dramatic manipulations of sodium balance in an older cohort may
provide greater insight into the relationship between salt and blood pressure. Overall,
substantial variation in intake (75 to 100 mmol/24 hours) can produce measurable but
modest changes in blood pressure. The effect appears to be more substantial in older
subjects and in those with higher pressures.
Age has been found to be significantly related to salt sensitivity of blood pressure
in the majority of studies.

Only a few studies using interventions to assess salt

sensitivity have included large enough numbers and a sufficient age range of subjects to
be able to identify such a relationship. Increasing salt sensitivity has been noted with
increasing age in several other studies (Weinberger, Miller, Luft, 1986; Osanai,
Kanazawa, Yokono, 1993; Overlack, Ruppert, Kolloch, et al., 1995). Additionally, this
relationship appears to be stronger in hypertensive than in normotensive individuals
(Weinberger, Fineberg, 1991). The mean age of participants in our study was 45 years,
and thus our data may be skewed given our young cohort. Given the youth of our
population, the occurrence of salt-sensitive hypertension is less prevalent, and would
reflect as less significance in the study findings.
Hypertensive patients, as a group, are significantly more salt sensitive than
normotensive individuals (Weinberger, Miller, Luft, 1986). Given that the participants
were all normotensive, the sample size would have to be significantly greater for
significance to be present. Based on the results for DDAH levels between salt loaded
(mean = 12.62, SD = 3.8) versus placebo groups (mean = 13.45, SD = 5.0), and
hypothesizing that people with higher salt load have lower DDAH levels compared to
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lower salt loaded participants; a post-hoc power analysis was done to determine the
level of power actually achieved to see if that’s a factor in the non-significant findings.
The power analysis revealed that 204 participants would be required for the crossover
study design to achieve 0.85 statistical power (alpha = 0.05) of detecting a mean
difference in DDAH levels between salt loaded and placebo groups. Therefore, the
selection criteria likely impacted these results, thus reflecting a major limitation to the
study, as the prevalence of salt-sensitive individuals is lower in normotensive versus
hypertensive patients.
By and large several limitations impacted the significance level in the study,
including a smaller sample size than expected, thus the difference noted may not have
allowed for significant changes to be established. Another major shortcoming was likely
the inadequate difference in the urine sodium:creatinine ratio at the end of the two time
periods. There may have been a lack of effect as there was not a full sodium load
secondary to lack of compliance with capsule ingestion.

Several participants

experienced side effects (i.e., nausea) due to the size of the capsules, or they may have
forgotten to take their capsules. When taking placebo, and presumably consuming a
100 mmol/day sodium diet, the urinary sodium:creatinine ratio was 0.8522.
supplementation

of

an

additional

100

mmol/day

should

double

the

The
urine

sodium:creatinine ratio; however, the urine sodium:creatinine ratio at the end of sodium
was only 1.2651. While the expected difference between the two treatment periods was
0.8522; the observed difference that was statistically significant was 0.4130. Thus,
0.4120/0.8522 = 0.485 or 48.5% of the expected difference between the two treatment
periods was ACTUALLY observed. The conclusion is that sodium supplementation did
indeed occur to a statistically significant degree but to a level that was slightly less than
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50% of predicted. This is clearly related to the problem with taking capsules, perhaps of
such a large size, as well as consuming high levels of sodium in concentrated amounts
causing nausea. This exercise makes some assumptions that may not be entirely
accurate - the linking of the urine sodium:creatinine ratio of 0.8522 to a dietary intake of
100 mmol of sodium per day - however, it is a very reasonable exercise to estimate how
short the dietary intake fell short of the projected amount if everyone would have taken
the sodium. In essence, the physiological changes seen occured with ~ 50 mmol of
difference in dietary sodium exposure between the two treatment periods. Additionally,
the patient population was basically normotensive, and this may have impacted the
change in DDAH, ADMA, and NO levels, as many patients may not have been salt
sensitive.
Overall, in a cohort of young, overweight, African American normotensive
women, sodium exposure was directly proportional to the difference in BP and there
was a reduction in DDAH level and NO metabolites, with significant indirect correlations
between DDAH, NO and augmentation index. This study attempted to characterize a
novel mechanism of action through which salt-induced depression of NO synthesis may
occur in normotensive African American individuals. Despite lack of significance in the
differences of DDAH, ADMA, and NO between the treatment groups, the combined
group results trended in the direction of the central hypothesis that increased dietary
sodium intake downregulates DDAH and depresses NO production, and revealed a rise
in BP and vascular stiffness. This initial study is the first demonstrating the trend that
increased sodium intake was associated with a reduction in DDAH activity, and a
depression in NO metabolites in healthy, normotensive African Americans. The findings
provide beginning evidence of the proposed linkages, but further study is warranted

51
given the aforementioned limitations. This was a small study used as basic exploratory
work to establish a plausible model for future research. The study advances knowledge
in the field of salt-sensitive hypertension by delineating a mechanism of action which
may be further studied to potentially target the prevention of elevated blood pressure.
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Salt sensitivity is associated with a rise in blood pressure (BP) occurring during
sodium loading and/or a fall in BP during sodium restriction that exceeds random
fluctuations in BP. Salt sensitivity is more common in African American than Caucasian
hypertensives and is also present, in normotensive African Americans. The mechanism
or mechanisms resulting in salt-sensitive hypertension are multiple and include both
activation of the renin angiotensin system via increases in angiotensin II and reductions
in the endogenous vasodilator, nitric oxide (NO).

An important means of NO

downregulation is through asymmetric dimethylarginine (ADMA), an endogenous NO
inhibitor,

which

is

largely

metabolized

by

the

enzyme

dimethylarginine

dimethylaminohydrolase (DDAH). The activity of DDAH is impaired by oxidative stress,
thereby permitting ADMA to accumulate thus resulting in further inhibition of NO.
Increases in oxidative stress, reduction in DDAH activity, and augmented action of
ADMA on depressing NO production represents a plausible mechanism in human salt
sensitivity. The study investigates and characterizes the above mechanism through
which salt-induced depression of NO synthesis occurs in normotensive African
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Americans. The study population was a cohort of mostly young (mean age 45 years,
SD = 6.0), female (87%), African Americans who were normotensive, and overweight.
The DDAH level and NO metabolites came down after sodium exposure (6.17% and
11.53%, respectively), while the BP rose (SBP: +2.8 mm Hg; DBP +0.8 mm Hg) and the
augmentation index (a measure of arterial stiffness) increased by almost 12% after
sodium

exposure,

though

not

statistically

significant.

The

difference

in

sodium:creatinine ratio was directly proportional to the change in BP (SBP: p = 0.01;
DBP p = 0.13), which likely mediated the BP effect. Additionally, NO metabolites and
DDAH levels were positively correlated to each other (r = 0.90; p = <0.0001), and
changes in both DDAH and NO levels were negatively correlated to changes in
augmentation index (DDAH: r = -0.61; p = 0.04; NO: r = -0.59; p = 0.05). As expected,
the DDAH and NO levels increased while the augmentation index decreased reflecting
a reduction in arterial stiffness.

Overall, in a cohort of young, overweight, African

American normotensive women, sodium exposure was directly proportional to the
difference in BP and there was a reduction in DDAH level and NO metabolites, with
significant indirect correlations between DDAH, NO, and augmentation index. Despite
lack of significance in the differences of DDAH, ADMA, and NO between the treatment
groups, the combined group results trended in the direction of the central hypothesis
that increased dietary sodium intake downregulates DDAH and depresses NO
production, resulting in a rise in BP and vascular stiffness. This initial study is the first
demonstrating the trend that increased sodium intake was associated with a reduction
in DDAH activity, and a depression in NO metabolites in healthy, normotensive African
Americans.
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